Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
hydroxamic acid |
| gptkbp:approvedBy |
1983 (US FDA)
|
| gptkbp:ATCCode |
G04BX03
|
| gptkbp:brand |
Lithostat
|
| gptkbp:CASNumber |
546-88-3
|
| gptkbp:chemicalFormula |
C2H5NO2
|
| gptkbp:contains_functional_group |
acetamide group
hydroxamic acid group |
| gptkbp:contraindication |
pregnancy
renal impairment |
| gptkbp:discoveredBy |
20th century
|
| https://www.w3.org/2000/01/rdf-schema#label |
acetohydroxamic acid
|
| gptkbp:IUPACName |
N-hydroxyacetamide
|
| gptkbp:KEGGID |
D00209
|
| gptkbp:meltingPoint |
85–86 °C
|
| gptkbp:MeSH_ID |
D000096
|
| gptkbp:molecularWeight |
75.07 g/mol
|
| gptkbp:PubChem_CID |
1913
1987 CHEMBL1201 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting headache rash |
| gptkbp:solubility |
soluble
|
| gptkbp:UNII |
6Q8XW47B1E
|
| gptkbp:usedFor |
treatment of urinary tract infections
treatment of struvite kidney stones urease inhibitor |
| gptkbp:bfsParent |
gptkb:urease
|
| gptkbp:bfsLayer |
7
|